Stock Market Strategy Amidst Strength in Robotics, Hanmi Pharmaceutical, and Cosmetics Stocks?

Robotics-related stock Everybot has recently seen a sharp rise in the market. This reflects increasing investor interest in the robotics industry as a whole and the prominence of related issues. The expert advised actively pursuing this strong trend from a short-term trading perspective.

KNR Systems, a robotics-related stock previously recommended by the expert, has continued its sharp rise, recording an approximate 80% return from the 10,000 won range to 18,000 won. This case demonstrates the sustained strength of the robotics sector, once again drawing investor attention.

Chinese robotics company Unitree surged over 490% in just one day after listing, reflecting the heated atmosphere of the global robotics market. Domestically, with Hyundai Motor's Investor Day presentation scheduled, demand for robotics-related stocks is concentrating, and Hyundai Motor itself is showing strength. This, coupled with expectations for Hyundai Motor's expanded investment in the robotics industry, is serving as a factor driving the overall upward trend in domestic robotics stocks.

Although Hanwha's stock price experienced an adjustment after its subsidiary's spin-off IPO, the expert recommended that holders not sell but continue to hold. Despite the temporary stock price drop due to the spin-off, Hanwha's intrinsic value and future growth potential are highly regarded.

Major construction stocks, including Hyundai E&C and Daewoo E&C, are showing solid performance and continuing their strong trend. In particular, as expectations grow for the construction of 8-9 large nuclear power plants in the Honam Industrial Complex, stock prices of nuclear power-related companies like Doosan Enerbility have also shown strength. This is interpreted as a positive market response to changes in government energy policy and large-scale infrastructure investment plans.

The expert advised against selling Hanmi Pharmaceutical and raised its target price to 600,000 won. This reflects expectations for new drug development and growth potential, indicating ample room for further stock price increase even after hitting the upper limit. It was emphasized that any short-term adjustments should be utilized as buying opportunities, and it is crucial to maintain a long-term holding perspective. In particular, Hanmi Pharmaceutical possesses numerous innovative new drug pipelines, and further stock price appreciation is anticipated based on future clinical trial results and commercialization news. The expert assessed that the current stock price is undervalued and has sufficient upside potential, urging continued interest.

Hanmi Pharmaceutical's obesity treatment UCN2 has an innovative mechanism that simultaneously promotes energy metabolism and controls appetite. This treatment offers a differentiated approach to obesity treatment by performing these two key functions in parallel. In particular, unlike existing obesity treatments, UCN2 induces fundamental weight loss by regulating energy metabolism and is expected to secure a unique position in the market as the first treatment of its kind.

Hanmi Pharmaceutical's new drug HM17321 aims to maximize sales through a two-track strategy, not only for monotherapy but also for combination therapy with Roche's pipeline. Such combination therapy is expected to create synergistic effects, enhance treatment efficacy, and ultimately contribute to Hanmi Pharmaceutical's sales growth. Furthermore, the company plans to systematize its milestone and royalty income structure to secure stable revenue streams.

Hanmi Pharmaceutical highlighted HM1527 as its key pipeline for the second half of the year. HM1527 is a new drug for the treatment of obesity and metabolic diseases, with the ability to manage various metabolic diseases simultaneously alongside its weight loss effects. This pipeline is expected to play a crucial role as Hanmi Pharmaceutical's future growth engine.

Hanmi Pharmaceutical possesses HM50019, a pipeline to prevent muscle loss, a common side effect of obesity treatments, and HM15136, a pipeline for treating chronic hypoglycemia. HM50019 inhibits muscle loss through a myostatin mechanism, enhancing obesity treatment efficacy while improving patients' quality of life. HM15136 provides stable blood sugar management for patients with chronic hypoglycemia, contributing to comprehensive health management for patients alongside obesity treatment.

Hanmi Pharmaceutical plans to announce at least six major new drug-related issues in the second half of the year, starting with the domestic commercialization and launch of Epiclutide. In particular, the announcement of Phase 2 clinical trial results with Merck (MSD) is expected, which could positively impact the stock price. Additionally, news of clinical progress for various other pipelines is anticipated to be a major driving force for sales and growth in the second half.

A strategy was presented to utilize a sharp drop in Hanmi Pharmaceutical's stock price as a buying opportunity. It is important to prevent a break below the 300,000 won level and maintain buying momentum, while a mid-to-long-term holding strategy is recommended over short-term stock price fluctuations. The expert advised focusing on Hanmi Pharmaceutical's long-term growth potential and identifying low-point buying timings through technical analysis.

In Hanmi Science, the management rights dispute and stake competition among major shareholders remain fierce. The movement of white knight forces and efforts to secure stakes are continuously mentioned, acting as factors that could affect Hanmi Science's stock price volatility. The expert predicted that this stake competition would likely continue for some time rather than being resolved in the short term.

In its Q2 earnings announcement, LG H&H reported a surge of over 47% in North American sales year-on-year, reaching 205.8 billion won. This demonstrates the successful implementation of its sales structure restructuring strategy, focusing on the North American market after the sale of Avon Company. In particular, the strong sales performance of its own brands, including Dr.Groot, CNP, Belif, and The Face Shop, in the North American market drove this growth. The performance of these brands is considered a crucial indicator of LG H&H's competitiveness and brand power in the global market.

Korea Cosmetics Manufacturing has garnered market attention by achieving a high return of over 82% in a short period after the expert's recommendation. The expert advised against selling this stock, suggesting accumulating it steadily, and emphasized the strategy of always investing primarily in leading companies. This is based on the belief that market-leading companies are more likely to generate high returns.

Expert Cho Seon-il demonstrated outstanding performance, ranking 2nd in cumulative mid-to-long-term returns and 1st in the short-term trading sector among over 30 experts. This signifies exceptional skill in both mid-to-long-term and short-term investing. Past successful strategies in major stocks like Samsung Electronics, SK Hynix, and Jusung Engineering were mentioned to highlight the effectiveness of his investment approach. Such achievements build trust among investors and raise expectations for the expert's investment advice.

Expert Cho Seon-il announced a special sign-up event to celebrate reaching 10,000 members on his Naver Band. This event will provide opportunities to gain profits with new leading stocks. Participants were encouraged to utilize the event to achieve significant returns.